Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22001 | 0.77 | TRPA1 (0.43) | TRPA1CYP1A2CYP2D6 | |
| SCHEMBL27882257 | 0.76 | TRPA1 (0.42) | TRPA1CYP1A2CYP2D6 | |
| SCHEMBL30218263 | 0.70 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL29394860 | 0.70 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL18894037 | 0.69 | — | — | |
| SCHEMBL2500373 | 0.68 | TRPA1 (0.34) | TRPA1CYP1A2CYP2D6 | |
| SCHEMBL11443028 | 0.65 | TRPA1 (0.36) | TRPA1 | |
| SCHEMBL11443029 | 0.65 | TRPA1 (0.36) | TRPA1 | |
| SCHEMBL15704080 | 0.65 | MAOA (0.34) | — | |
| SCHEMBL3092641 | 0.65 | TRPA1 (0.41) | TRPA1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116832869-A | Magnetic nano bimetallic catalyst and preparation method and catalytic application thereof | 河北师范大学 | 2023-10-03 | — | — | CN | claimed |
| EP-2560973-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2016-11-16 | — | — | EP | claimed |
| EP-2560973-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbvie Inc. (US) | 2013-02-27 | — | — | EP | claimed |
| EP-2421870-A2 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2012-02-29 | — | — | EP | claimed |
| WO-2011133182-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-10-27 | — | — | WO | claimed |
| EP-0673371-A1 | BENZAZEPINONE DERIVATIVES | Novartis AG (CH) | 1995-09-27 | — | — | EP | claimed |
| WO-1994013651-A1 | BENZAZEPINONE DERIVATIVES | CIBA-GEIGY AG (CH) | 1994-06-23 | — | — | WO | claimed |
| EP-4611792-A1 | THERAPEUTIC REGIMENS AND METHODS FOR TREATMENT OF CARDIOVASCULAR RISK FACTORS USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-119859127-A | Benzooxazepines and benzoxazoles Synthesis method and application of class compound | 东北林业大学 | 2025-04-22 | — | — | CN | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| WO-1990006309-A1 | HETEROAZABENZOBICYCLIC CARBOXAMIDE 5-HT3, ANTAGONISTS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1990-06-14 | — | — | WO | disclosed |
| US-4933445-A | Heteroazabenzobicyclic carboxamide 5-HT3 antagonists | RORER PHARMACEUTICAL CORPORATION (US) | 1990-06-12 | — | — | US | disclosed |
| US-4251534-A | Antihypertensive polyfluorohydroxyisopropyl bicyclic and tricyclic carbostyrils | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
| US-4238607-A | ANTIBIOTICS, SEDATIVES, HYPOTENSIVE AGENTS, AND ANTIDEPRESSANTS | ENDO LABORATORIES INC. (US) | 1980-12-09 | — | — | US | disclosed |
| US-4183936-A | SEDATIVES, ANTIDEPRESSANTS, HYPOTENSIVE AGENTS, BACTERICIDES | ENDO LABORATORIES, INC. (US) | 1980-01-15 | — | — | US | disclosed |
| US-4115577-A | SEDATIVES, ANTIDEPRESSANT ANTIHYPERTENSIVE, ANTIBACTERIAL | ENDO LABORATORIES, INC. (US) | 1978-09-19 | — | — | US | disclosed |
| US-4013652-A | SEDATIVES | ENDO LABORATORIES, INC. (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | TRPA1 4789/4885CYP1A2 61/4885CYP2D6 159/4885 |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | TRPA1 4777/4885CYP1A2 3890/4885CYP2D6 3837/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | TRPA1 4793/4885CYP1A2 4131/4885CYP2D6 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.